Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials

Graphical Abstract Graphical Abstract TG-lowering treatments and atherosclerotic CV disease risk. A TG-lowering approach that results in TG lowering with no effect on apoB levels provides no clinical benefit; indeed, CV risk reduction is achievable when TG-lowering is accompanied by a reduction in a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European heart journal 2024-07, Vol.45 (27), p.2377-2379
Hauptverfasser:	Tokgözoğlu, Lale, Pirillo, Angela, Catapano, Alberico Luigi
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular Diseases - prevention & control Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Hypertriglyceridemia Hypolipidemic Agents - therapeutic use Randomized Controlled Trials as Topic Triglycerides - blood Triglycerides - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Graphical Abstract Graphical Abstract TG-lowering treatments and atherosclerotic CV disease risk. A TG-lowering approach that results in TG lowering with no effect on apoB levels provides no clinical benefit; indeed, CV risk reduction is achievable when TG-lowering is accompanied by a reduction in apoB levels. TG: triglyceride; CE: cholesteryl ester; apoB: apolipoprotein B; CV: cardiovascular.
ISSN:	0195-668X 1522-9645 1522-9645
DOI:	10.1093/eurheartj/ehad485